Dr. Michael Lester Haas, MD

Dr. Haas practices at Reading Hospital in West Reading, Pennsylvania, part of Tower Health.

Dr. Haas' NPI, 1528010063, was assigned on May 16, 2006. Dr. Haas graduated from Rutgers Robert Wood Johnson Medical School in 1996. Dr. Haas holds Pennsylvania license MD072980L.

Dr. Haas' primary practice is Reading Hospital, at 420 S 5th Avenue, West Reading, PA 19611 in Berks County. The practice phone is (610) 988-8000.

Dr. Haas' primary practice is Reading Hospital in West Reading, Pennsylvania, part of Tower Health. The medical group on file is Reading Hospital Cardiology - West Reading. Dmand AI also links Dr. Haas to 1 more physician office, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Haas practices, 2 sites in all. Vendor and product names are available with a free account.

Radiation oncology is Dr. Haas' primary specialty in the NPI Registry, under taxonomy code 2085R0001X. Dr. Haas is board certified in radiation oncology by the American Board of Radiology. Dr. Haas is licensed in Pennsylvania.

Dmand AI lists bladder cancer radiation, bone cancer radiation, brain cancer radiation, breast cancer radiation, cervical cancer radiation, head & neck cancer radiation, lung cancer radiation and prostate cancer radiation among the conditions Dr. Haas treats.

CMS data shows 2,418 Medicare services from Dr. Haas across 21 procedure codes in 2024, for 365 Medicare patients. Medicare paid $167,749 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 365 Medicare patients who saw Dr. Haas in 2024. The largest group is 65 to 74, with 183 patients. 75% of them have cancer, and 75% have high blood pressure. 9% are also on Medicaid. Their average risk score is 1.63, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Haas' median patient age at 70, with 49% women.

In 2024, Dr. Haas wrote 165 Medicare Part D claims for 89 patients. 94% of them were for generic drugs. CMS names the drug for 97 of them, across 3 drugs with 11 or more claims each, at $860 in total drug cost. In 2023, CMS named 55 claims across 2 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 88 out of 100 for Dr. Haas for performance year 2024, reported as part of a group. Dr. Haas accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 9 papers to Dr. Haas, published from 2013 to 2025. 2017 was the busiest year, with 2. The most frequent topics are Radiotherapy, Intensity-Modulated, Patient Reported Outcome Measures and Uterine Cervical Neoplasms. Dr. Haas has published most often in Gynecol Oncol. Dr. Haas' most frequent co-authors are Desiree Elaine Doncals, MD, Lisa Ann Kachnic, MD and Ann H. Klopp, MD, PhD.

Dmand AI links Dr. Haas to 10 clinical trials, 4 of them phase 3 studies. 10 are still active or recruiting. Conditions studied include Glioblastoma, Gliosarcoma and Anal Canal Carcinoma. National Cancer Institute (NCI) sponsors the most, 6.

CMS Open Payments shows 30 general payments to Dr. Haas from 8 drug and device companies from 2016 to 2025. Honoraria make up the largest share, 49% of the total. Novocure Inc. paid the most, $5,174.

Dr. Haas graduated from Rutgers Robert Wood Johnson Medical School in 1996. Dr. Haas is a member of ASCO.

Dr. Haas is in network with 19 carriers, including Aetna, Elevance and HCSC. PPO plans come from the most carriers, 12. Check the plan with the practice before a visit.